Who We Are
Boundless Bio's Pioneering Team
Developing an entirely new class of therapeutics requires boldness, commitment, creativity, and an entrepreneurial spirit. We are building a team of pioneers committed to driving a scientific revolution in how the most difficult-to-treat cancers are understood and treated. Above all else, our commitment is to the patients we strive to help. We aim to create the first therapeutics capable of dismantling one of cancer’s trickiest evasive mechanisms – ecDNA.
Board Of Directors
Paul Mischel, M.D.
Institute Scholar, ChEM-H; Vice Chair of Research and Professor, Dept of Pathology, Stanford University Chairman of the Scientific Advisory Board
Stephen Benkovic, Ph.D.
Evan Pugh University Professor and Eberly Chair in Chemistry at The Pennsylvania State University
Howard Chang, M.D., Ph.D.
Virginia and D.K. Ludwig Professor of Cancer Genomics and Genetics at Stanford University